![Amgen Inc Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/amgn.png?tr=w-200)
Amgen Inc
NASDAQ:AMGN
![Amgen Inc Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/amgn.png)
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
230.41
335.97
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Realty Income Corp
NYSE:O
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/amgn.png)
Intrinsic Value
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. [ Read More ]
The intrinsic value of one
AMGN
stock under the Base Case scenario is
240.57
USD.
Compared to the current market price of 334.55 USD,
Amgen Inc
is
Overvalued by 28%.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/amgn.png?tr=w-200)
Valuation Backtest
Amgen Inc
Run backtest to discover the historical profit from buying and selling
AMGN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Amgen Achieves 22% Revenue Growth and Strong Product Advancements
Earnings Call Summary
In Q1 2024, Amgen reported $7.4 billion in revenue, marking a 22% increase from the previous year, driven by 25% volume growth. Key products like Repatha and TEZSPIRE saw significant improvement, with sales up by 33% and 80%, respectively. Newly acquired Horizon Therapeutics contributed $900 million to product sales. Operating expenses increased by 33%, reflecting investments in late-stage pipeline medications. Amgen forecasts 2024 revenues between $32.5 billion and $33.8 billion and non-GAAP EPS from $19 to $20.20. Significant pipeline advancements include Phase III trials for MariTide and tarlatimab, positioning Amgen for continued growth.
Balance Sheet Decomposition
Amgen Inc
Current Assets | 28B |
Cash & Short-Term Investments | 9.7B |
Receivables | 6.8B |
Other Current Assets | 11.5B |
Non-Current Assets | 65B |
PP&E | 6B |
Intangibles | 49.9B |
Other Non-Current Assets | 9B |
Current Liabilities | 19.7B |
Accounts Payable | 1.6B |
Accrued Liabilities | 14.1B |
Other Current Liabilities | 4B |
Non-Current Liabilities | 68.2B |
Long-Term Debt | 60.1B |
Other Non-Current Liabilities | 8.2B |
Earnings Waterfall
Amgen Inc
Revenue
|
29.5B
USD
|
Cost of Revenue
|
-9.9B
USD
|
Gross Profit
|
19.6B
USD
|
Operating Expenses
|
-12.5B
USD
|
Operating Income
|
7.1B
USD
|
Other Expenses
|
-3.3B
USD
|
Net Income
|
3.8B
USD
|
Free Cash Flow Analysis
Amgen Inc
USD | |
Free Cash Flow | USD |
AMGN Profitability Score
Profitability Due Diligence
Amgen Inc's profitability score is 75/100. The higher the profitability score, the more profitable the company is.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/amgn.png)
Score
Amgen Inc's profitability score is 75/100. The higher the profitability score, the more profitable the company is.
AMGN Solvency Score
Solvency Due Diligence
Amgen Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/amgn.png)
Score
Amgen Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AMGN Price Targets Summary
Amgen Inc
According to Wall Street analysts, the average 1-year price target for
AMGN
is 326.65 USD
with a low forecast of 171.7 USD and a high forecast of 399 USD.
Ownership
AMGN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Price Appreciation
AMGN Price
Amgen Inc
Average Annual Return | 14.36% |
Standard Deviation of Annual Returns | 18.43% |
Max Drawdown | -1% |
Market Capitalization | 179.5B USD |
Shares Outstanding | 536 000 000 |
Percentage of Shares Shorted | 1.68% |
AMGN News
Last Important Events
Amgen Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Amgen Inc
Company Profile
![Amgen Inc Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/amgn.png?tr=w-200)
![Amgen Inc Logo](https://ik.imagekit.io/kkbzr2uz4cp/stock/nasdaq/amgn.png?tr=w-200)
Country
Industry
Market Cap
Dividend Yield
Description
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 24,200 full-time employees. The firm discovers, develops, manufactures and delivers various human therapeutics. The company operates in human therapeutics segment. Its marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The firm focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
Contact
IPO
Employees
Officers
The intrinsic value of one
AMGN
stock under the Base Case scenario is
240.57
USD.
Compared to the current market price of 334.55 USD,
Amgen Inc
is
Overvalued by 28%.